Liarozole

Overview

Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA) . Liarozole inhibits the cytochrome P450 ( CYP26 )-dependent 4-hydroxylation of retinoic acid ( IC 50 =7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Vitamin D Related/Nuclear Receptor | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > RAR/RXR

Product Information

• Catalog No.: HY-106019
• CAS No.: 115575-11-6
• Molecular Formula: C17H13ClN4
• Molecular Weight: 308.76
• Purity: 98.96%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.5 mg/mL (8.10 mM); Clear solution
• Availability: In-stock

Source

Original product source